| Identification | Back Directory | [Name]
L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, monoacetate (salt) (9CI) | [CAS]
442526-87-6 | [Synonyms]
ABT510 acetate
ABT-510 acetate
ABT 510 acetate
L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, monoacetate (salt) (9CI) | [Molecular Formula]
C48H87N13O13 | [MOL File]
442526-87-6.mol | [Molecular Weight]
1054.3 |
| Hazard Information | Back Directory | [Uses]
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2]. | [in vivo]
ABT-510 acetate (100 mg/kg; i.p.; single daily for 90 days) induces cells apoptosisin vivo and leads to a significant reduction in epithelial ovarian tumor size, ascites fluid volume, and secondary lesion dissemination in mice[1].
ABT-510 acetate (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease[2].
| Animal Model: | TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer)[1] | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneal injection; single daily for 90 days | | Result: | Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice.
Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions.
Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels.
|
| Animal Model: | TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model)[2] | | Dosage: | 60 mg/kg | | Administration: | Subcutaneously implanted osmotic minipumps (0.5μL/h); single daily for 7 days | | Result: | Significantly delayed DSS-induced bleeding and improved the overall severity of disease.
Significantly diminished inflammation grading and angiogenesis.
|
| [References]
[1] Greenaway J, et.al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74. DOI:10.1158/1535-7163.MCT-08-0864
[2] Punekar S,et.al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21. DOI:10.1159/000113790
[3] Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2008 Feb 15;75(4):875-82. DOI:10.1016/j.bcp.2007.10.025 |
|
|